Shore N., Heidenreich A., Villers A., Klotz L., Hussain M., Karsh L., van Os S., Baron B., Wang F., Forer D., Chowdhury S., Siemens R. D.   TERRAIN TRIAL: PROSTATE-SPECIFIC ANTIGEN KINETICS AND QUALITY OF LIFE RESULTS OF ENZALUTAMIDE VERSUS BICALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.  J. Urol..  2015 ;193 :E496-E496
Sekulic A., Migden M. R., Basset-Seguin N., Garbe C., Gesierich A., Lao C., Miller C. J., Mortier L., Murrell D. F., Hamid O., Quevedo J. F., Hou J., Tripathi M.   Long-termsafety and efficacy of vismodegib in patients with advanced basal cell carcinoma: 30-month final update of the pivotal ERIVANCE BCC study.  J. Am. Acad. Dermatol..  2015 ;72 :AB187-AB187
Sekulic A., Hainsworth J. D., Lewis K. D., Oro A. E., Gesierich A., Mortier L., Dirix L., Bernard S., Dreno B., Murrell D. F., Williams S., Hou J., Fisher D.   Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.  J. Am. Acad. Dermatol..  2015 ;72 :AB195-AB195
Schoots I. G., Petrides N., Giganti F., Bokhorst L. P., Rannikko A., Klotz L., Villers A., Hugosson J., Moore C. M.   Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review.  Eur. Urol..  2015 ;67 :627-636

CONTEXT: There is great interest in using magnetic resonance imaging (MRI) for men on active surveillance for prostate cancer. OBJECTIVE: To systematically review evidence regarding the use of MRI in men with low- or intermediate-risk prostate cancer suitable for active surveillance. EVIDENCE ACQUISITION: Ovid Medline and Embase databases were searched for active surveillance, prostate cancer, and MRI from inception until April 25, 2014 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. EVIDENCE SYNTHESIS: A lesion on MRI suspicious for prostate cancer (positive MRI) is seen in two-thirds of men otherwise suitable for active surveillance. A positive MRI makes the identification of clinically significant disease at repeat biopsy more likely, especially when biopsies are targeted to suspicious MRI lesions. Radical prostatectomy data show that positive MRI is more likely to be associated with upgrading (Gleason score>3+3) than a negative MRI (43% vs 27%). A positive MRI is not significantly more likely to be associated with upstaging at radical prostatectomy (>T2) than a negative MRI (10% vs 8%). Although MRI is of interest in the monitoring of men on active surveillance, robust data on the use of repeat MRI in active surveillance are lacking. Prospective studies with clear definitions of radiological significance and progression are needed before this approach can be adopted. CONCLUSIONS: MRI is useful for detection of clinically significant disease at initial assessment of men considering active surveillance. To use MRI as a monitoring tool in surveillance, it will be necessary to define both radiological significance and radiological progression. PATIENT SUMMARY: This review assesses evidence for the use of magnetic resonance imaging (MRI) in men on active surveillance for prostate cancer. MRI at the start of surveillance can detect clinically significant disease in one-third to half of men. There are few data to assess the use of MRI as a monitoring tool during surveillance, so there is a need to define significant disease on MRI and significant changes over time.

Scalbert C., Grenier M., Maire C., Cottencin O., Bonnevalle A., Behal H., Duhamel A., Glantenet R., Mortier L.   Indoor tanning: Motivations and beliefs among users and non-users in the population of Lille (Northern France).  Ann. Dermatol. Venereol..  2015 ;142 :10-16

BACKGROUND: Uncontrolled use of tanning beds is a major public health problem. The role of UV in skin carcinogenesis has in fact been clearly demonstrated. AIMS: The main purpose of the study was to assess the motivations and beliefs of the population concerning the use of indoor tanning. The secondary objectives were to compare the knowledge of users and non-users and to screen for addiction criteria among users. PATIENTS AND METHODS: This was a transversal descriptive study conducted between April and June 2013 in Lille town center. The motivations of the participants were determined using a multiple-choice questionnaire. A Likert scale was used to assess beliefs and an m-CAGE questionnaire was used to screen for addiction. RESULTS: Of the 200 respondents, 30% (n=60) had used tanning beds in a non-medical setting. The median age of first use was 23 years (15-59). 11.7% of respondents had started before the authorised age of 18 years. "To prepare the skin for exposure to the sun" was the main reason given (68.3%) for use of tanning beds. The population was aware that use of such apparatus favours onset of skin cancer and ageing of the skin. Users were more convinced than non-users that UV cabins "prepare the skin for exposure to the sun" (75% vs. 49.6%, P=0.0009) and that they "favour skin cancer" (56.9% against 36.2%, P=0.0444). Addictive behaviour was detected in 3.3% (2/60) of users. CONCLUSION: Users are aware of the carcinogenic risk of UV cabins but expose themselves to such risk, as they believe it prepares their skin for sun exposure.

Sassolas B., Grange F., Touboul C., Lebbe C., Saiag P., Mortier L., Lhomel C., Robert C.   Sun exposure profile in the French population. Results of the EDIFICE Melanoma survey.  J. Eur. Acad. Dermatol. Venereol..  2015 ;29 :6-10

BACKGROUND: The incidence of melanoma is increasing worldwide, causing significant economic burden at community and individual levels. Ultraviolet radiation, from natural sunlight or artificial sources, is the main environmental, modifiable risk factor for melanoma. OBJECTIVES: The present analysis assesses the profile of sun exposure in the French population as well as the level of awareness about ultraviolet risk and protection. METHODS: The survey was conducted via telephone interviews in September and October 2011. In total, 1502 respondents were questioned about their own sun exposure with the question "do you ever, even occasionally, spend time in the sun, during leisure-time, vacation or your professional occupation?" They were also asked about sun protection measures used: protective clothing, a hat or sunscreen. RESULTS: More than three respondents out of four (78%) declared exposing themselves to the sun, with an average of 113 days per year. Of these, 38% did not use appropriate sun protection measures. We identified the following characteristics of individuals declaring high sun exposure: chiefly men under the age of 40, higher socio-professional levels, and adults with no children. Individuals who make a poor use of protective measures are mostly men and of low educational levels. Individuals declaring low sun exposure were chiefly: women, individuals over the age of 60, and those with no professional activity. The high sun protection population comprises mostly: women, higher socio-professional levels, with no specific age-group profile. CONCLUSIONS: Analysis of the EDIFICE Melanoma survey provides information about the attitudes of the French population towards sun exposure. The most frequent contexts of sun exposure and the associated socio-demographic characteristics of the population with at-risk attitudes regarding sun exposure are identified. This deeper insight into the profile of at-risk populations will allow interventions to be more accurately targeted, thus potentially improving public health benefits.

Sakji-Dupre L., Le Rhun E., Templier C., Desmedt E., Blanchet B., Mortier L.   Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.  Melanoma Res..  2015 ;25 :302-305

Anti-BRAF agents, including vemurafenib, have modified the prognosis for patients with melanoma. However, a difference can still be observed between extracerebral and cerebral responses. The aim of this study was to investigate the diffusion of vemurafenib in cerebrospinal fluid (CSF) from patients treated for brain metastatic BRAF-V600 mutated melanoma. Six patients treated with vemurafenib 960 mg twice daily were included. These patients had undergone a lumbar puncture because of suspicions of leptomeningeal metastasis, along with simultaneous blood sampling to measure vemurafenib level. The concentrations of vemurafenib in the CSF and the plasma were measured by high-performance liquid chromatography. The mean plasma and CSF concentrations of vemurafenib were 53.4+/-26.2 and 0.47+/-0.37 mg/l, respectively. The mean ratio of the CSF : plasma concentration was 0.98+/-0.84%. No relationship was found between plasma and CSF concentrations (P=0.8). In conclusion, our preliminary results highlight for the first time a low CSF vemurafenib penetration rate associated with a large interindividual variability in patients treated for metastatic BRAF-V600 mutated melanoma and brain metastases. Further investigations with larger cohorts are required to study the relationship between CSF vemurafenib concentrations and cerebral response.

Saiag P., Sassolas B., Mortier L., Grange F., Robert C., Lhomel C., Lebbe C.   EDIFICE Melanoma survey: knowledge and attitudes on melanoma prevention and diagnosis.  J. Eur. Acad. Dermatol. Venereol..  2015 ;29 :11-15

BACKGROUND: Melanoma incidence is increasing worldwide thus justifying information campaigns aimed at reducing ultraviolet exposure levels and promoting early diagnosis. OBJECTIVES: We set out to assess awareness, knowledge and attitudes of the French population with regard to melanoma prevention and early diagnosis, following more than 15 years of nationwide information campaigns. METHODS: The French nationwide observational survey, EDIFICE Melanoma, was conducted after the summer (September to October 2011) through structured telephone interviews of a representative sample of 1502 individuals aged >/=18 years, using the quota method. All French regions were represented. RESULTS: Respondents had heard of sun-induced skin damage: 92% knew that sun increases melanoma risk. Knowledge of sun-protection measures was also good: 97% correctly cited at least one method of photoprotection (clothing 80%, sunscreens 69%) and 97% declared that sun exposure should be reduced between 12 pm and 4 pm in France. Knowledge of melanoma was encouraging: 70% of respondents could define the disease accurately and 60% knew the ABCDE rule for early diagnosis. However, self-tanning and sunbed use were considered by 25% and 13% of respondents, respectively, to provide protection from skin cancer. Although 43% of respondents (58% of high-risk respondents) declared they had consulted a doctor at least once for a suspect skin lesion, their actual behaviour was less encouraging: 30% declared never or almost never protecting their skin; 25% declared regularly checking their skin for atypical nevi; 12% declared checking the entire skin surface. Declared behaviour was better in fair-skin responders and those with a history of sunburn or skin cancer. CONCLUSIONS: Awareness of melanoma, early-diagnosis procedures and preventive behaviour has improved in the general French population since 1990. However, despite the good level of information, numerous misconceptions persist. Improved information campaigns in the future may help reduce the ever-increasing incidence of melanoma in France.

Rousseau J., Migonney V., Vermandel M.   Founder of the journal ITBM Yves Moschetto passed away In memoriam.  IRBM.  2015 ;36 :198-198
Rousseau J., Migonney V., Vermandel M.   In memoriam Death of Yves Moschetto, founder of the Innovation in Biological and Medical Technology Magazine, has works published, Professor.  IRBM.  2015 ;36 :197-197